Yusuf Abrahim, Sarika Sharma, K. Daniel, V. Daniel
{"title":"Immunity is Affected by Viral Cancer- A Review","authors":"Yusuf Abrahim, Sarika Sharma, K. Daniel, V. Daniel","doi":"10.2875/.V1I1.5","DOIUrl":null,"url":null,"abstract":"ABSTRACT- T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of onself and the prevention of autoimmunity. Identification of cancer cell T cell inhibitory signals, includingPD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hindersmmune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune re-sponses. The presence of suppressive factors in the tumor microenvironment may explain the limited activityobserved with previous immune-based therapies and why these therapies may be more effective in combi-nation with agents that target other steps of the cycle. Emerging clinical data suggest that cancer immuno-therapy is likely to become a key part of the clinical management of cancer Keywords- Immunity, Virus ,Cancer, Human Papillomavirus,Therapy.","PeriodicalId":18198,"journal":{"name":"生命科学研究","volume":"196 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2014-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"生命科学研究","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2875/.V1I1.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
ABSTRACT- T cell responses that recognize and eradicate cancer cells. However, elimination of cancer by T cells is only one step in the Cancer-Immunity Cycle, which manages the delicate balance between the recognition of onself and the prevention of autoimmunity. Identification of cancer cell T cell inhibitory signals, includingPD-L1, has prompted the development of a new class of cancer immunotherapy that specifically hindersmmune effector inhibition, reinvigorating and potentially expanding preexisting anticancer immune re-sponses. The presence of suppressive factors in the tumor microenvironment may explain the limited activityobserved with previous immune-based therapies and why these therapies may be more effective in combi-nation with agents that target other steps of the cycle. Emerging clinical data suggest that cancer immuno-therapy is likely to become a key part of the clinical management of cancer Keywords- Immunity, Virus ,Cancer, Human Papillomavirus,Therapy.